News Releases

November 4, 2025

Mexico’s SADER Approves MSD Animal Health’s EXZOLT® 5% Pour-On (Fluralaner 50 mg/mL) for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (Myiasis)

Veterinarians and cattle producers in Mexico have access to a new tool to protect cattle from New World Screwworm, helping to safeguard Mexico’s beef supply RAHWAY, N.J., November 4, 2025 – – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the Secretaria de Agricultura y Desarrollo Rural […]

October 23, 2025

New Data from MSD Animal Health Demonstrates that Intranasal Vaccination Against Bovine Coronavirus with BOVILLIS® NASALGEN®-C (Lyophilisate and Solvent for Suspension for Cattle) Significantly Improves Production in Veal Calves

Vaccinated calves showed fewer lung lesions and achieved a significantly higher body weight than unvaccinated calves Rahway, N.J., October 23, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the presentation of new data in support of intranasal vaccination for the prevention of bovine coronavirus (BCoV) […]

September 26, 2025

MSD Animal Health Presents New Data Demonstrating the Safety, Efficacy and Quick Onset of Injectable Formulation of BRAVECTO® (fluralaner) at World Small Animal Veterinary Association Congress

Additional educational symposia offer the latest information on vector-borne diseases, infectious diseases and treatment and prevention protocols Rahway, NJ, August 18, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will present multiple studies in support of the BRAVECTO® fluralaner portfolio at the 2025 World […]

September 25, 2025

MSD Animal Health Strengthens Its Dedication to Rabies Elimination with 7 Millionth Vaccine Donation Through the Afya Program

Rahway N.J., September 26, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has donated more than seven million NOBIVAC® rabies vaccines through the Company’s Afya Program, since it was founded. “Communities experiencing ongoing rabies outbreaks often lack essential resources and vaccines,” stated Ingrid Deuzeman, director of […]

September 12, 2025

MSD Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress

Rahway, N.J. – Sept. 13, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new data demonstrating the safety and efficacy of NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for dogs. These data were presented at the 35th […]

September 9, 2025

MSD Animal Health Launches NUMELVI® (atinvicitinib) Tablets for Dogs – A Veterinary Innovation in Fast, Effective and Safe Targeted Itch Relief

NUMELVI, a highly-selective, second-generation JAK inhibitor for dogs, delivers at least 10-fold greater selectivity for JAK1 compared with JAK2, JAK3, and tyrosine kinase (TYK)–2, and is suitable for dogs as young as 6 months. RAHWAY, N.J., July 24, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today […]

August 19, 2025

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New MSD Animal Health Global Survey Finds

Data show pet owners face difficulties with consistent compliance, while veterinarians worry about inconsistent or incorrect medication administration In the U.S. Two-thirds of veterinarians note that most pet owners do not follow year-round treatment plan, despite evidence that fleas and tick are present during all seasons RAHWAY, N.J., August 19, 2025 – MSD Animal Health, […]

August 18, 2025

MSD Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress

Data to showcase depth and breadth of the BRAVECTO® (fluralaner) portfolio including the injectable and oral endectocide combination formulations Rahway, NJ, August 18, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will present multiple studies in support of the BRAVECTO® fluralaner portfolio at the […]

July 24, 2025

European Commission Approves NUMELVI™ (atinvicitinib) Tablets for Dogs

NUMELVI from MSD Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., July 24, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., […]

July 10, 2025

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from MSD Animal Health

12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J., July 10, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) […]